Inflammatory bowel disease stories

Aug 28, 2026

FDA Approves Stelara for Pediatric Ulcerative Colitis

The FDA approved ustekinumab (Stelara) on August 28, 2026 for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older, making it the first non-TNF biologic approved for pediatric IBD.

Aug 28, 20261 source

Apr 13, 2026

Spyre Therapeutics IBD Drug Shows Promise in Early-Stage Trial

Spyre Therapeutics' inflammatory bowel disease therapy succeeded in its first major clinical testing, setting up competition with several large pharmaceutical companies in the IBD space.

Apr 13, 20261 source